MedTrace Logo

Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20)

NCT00310232 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2024-04-02

No results posted yet for this study

Summary

The general objective of this study is to improve the Quality of Life (QoL) of selected patients with advanced carcinoma of the lung. The specific objective is to evaluate the effect of treatment with epoetin alfa (recombinant human erythropoietin) on anemia related QoL and anemia in non-small cell lung cancer patients with advanced stage disease and underlying anemia of malignancy.

Conditions

Interventions

DRUG

Epoetin Alfa

Sponsors & Collaborators

  • Ortho Biotech, Inc.

    collaborator INDUSTRY

  • Ontario Clinical Oncology Group (OCOG)

    lead OTHER

Principal Investigators

  • Jim Wright, MD · Hamilton Regional Cancer Centre

  • Mark Levine, MD · Ontarion Clinical Oncology Group

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-02-28
Completion
2004-04-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00310232 on ClinicalTrials.gov